A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Latest Information Update: 16 Dec 2019
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms NUANCE
- 09 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 25 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.